Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD

Video

The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Omar Nadeem, MD, clinical director, Myeloma Cellular Therapies Program, physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, about the uptake of novel therapies in heavily pretreated multiple myeloma.

Nadeem discussed how therapeutic additions are welcome in the setting of heavily relapsed/refractory multiple myeloma. Although frontline therapies are prolonging life, multiple myeloma remains incurable and more patients progress to triple-class refractory disease, Nadeem explains.

Novel therapies, such as selinexor (Xpovio), belantamab mafodotin-blmf (Blenrep), melphalan flufenamide (Pepaxto), and idecabtagene vicleucel (Abecma), are available options for patients who have progressed on an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody, Nadeem explains.

Treatment decisions should be based on the unique mechanisms of action of these agents, differences in administration, and potential toxicities, Nadeem says. Additionally, patient factors, such as frailness, oral vs intravenous therapy preference, and renal function, should be taken into consideration when selecting treatment, concludes Nadeem.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.